Evidence map›Paper›PMID 30373594›Full record

ArticleBMC systems biology2018

The anticancer mechanism investigation of Tanshinone II

Yan-Feng Cao, Shi-Feng Wang, Xi Li, Yan-Ling Zhang, Yan-Jiang Qiao

Open access · diamondAbstract read
In one paragraph

Article in BMC systems biology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 25 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Frontiers in pharmacology · 2022
    Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Yan-Feng CaoSchool of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, 100102, China.
Shi-Feng WangSchool of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, 100102, China.
Xi LiSchool of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, 100102, China.
Yan-Ling ZhangSchool of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, 100102, China. collean_zhang@163.com.
Yan-Jiang QiaoSchool of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, 100102, China. yjqiao@bucm.edu.cn.
Beijing University of Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCancer is the second most common cause of death globally. The anticancer effects of Tanshinone II

methodAgilent Literature Search (ALS), a text-mining tool, was used to pull protein targets of Tan II

resultsA total of 258 proteins regulated by Tan II

conclusionsThe current study provides a systematic methodology for discovering the coordination of the anticancer pathways regulated by Tan II

Indexed as

Computational BiologyAbietanesAntineoplastic AgentsApoptosisAutophagyCell Cycle CheckpointsCell Line, TumorGene OntologyHumansNeovascularization, PathologicAbietanesAntineoplastic AgentstanshinoneAntineoplastic agentsNetwork pharmacologyPharmacological clusteringTanshinone IIA

Identifiers

PMID30373594
PMCPMC6206912
OpenAlexW2899088343

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.